Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Aug 3, 2015
Insider Transaction Report
Form 4
Rosiello Robert L.
EVP, Chief Financial Officer
Transactions
- Purchase
Common Stock, no par value
2015-07-31$257.25/sh+704$181,104→ 441,675 total - Purchase
Common Stock, no par value
2015-07-30$253.99/sh+7,171$1,821,362→ 440,971 total
Footnotes (1)
- [F1]This number represents the weighted average purchase price for all sales of common stock purchased by the reporting officer.